Kate Yen, Auron Therapeutics founder and CEO
July 20, 2022 10:56 AM EDTUpdated 02:07 PM
Financing
Startups

Armed with a $48M Se­ries A, Au­ron is look­ing to ap­ply ma­chine learn­ing in can­cer treat­ment

Tyler Patchen

News Reporter

The hype of ma­chine learn­ing has man­aged to bag se­ri­ous cash from in­vestors over the past year, and the lat­est biotech to en­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times